Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2021 · 10-Q
Revenue$14.68M$14.68M+2.4% vs Q1 2020 Net Income-$7.38M-$7.38MN/M vs Q1 2020 EPS Diluted-$0.12-$0.12N/M vs Q1 2020 Gross Profit$9,234,000+11.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$5,405,000N/M Margins · derivedGross margin62.9%+5.0 pt vs Q1 2020
Operating margin-50.1%−9.1 pt vs Q1 2020
Net margin-50.3%−9.1 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end